The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )

Study Purpose

The purpose of this study is to determine if vitamin D as an adjuvant therapy can improve the outcome (i.e. fewer relapses) and the quality of life, including levels of physical activity, in children diagnosed Crohn's disease (CD).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 4 Years - 18 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Age at randomization between 4 and 17 years inclusively 2. Pediatric Crohn's Disease Activity Index (PCDAI) ≤ 10 with no clinical symptoms (abdominal pain or blood in the stool) at inclusion 3. Receiving a stable dose for at least 4 weeks of any of the following drugs: Thiopurines, Methotrexate, or TNF-α inhibitors (Infliximab/Adalimumab) 4. Dosage of fecal calprotectin lower than 250 µg/g stool at inclusion.

Exclusion Criteria:

1. History of surgery resulting in a permanent colostomy or ileostomy (because of the inability to calculate PCDAI at baseline) 2. Patients who have already been included in the pilots vitamin D trials 3. Patients actively enrolled in other CD drug trials.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03999580
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Jantchou Prevost
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Prevost Jantchou, MD,PhD
Principal Investigator Affiliation St. Justine's Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Not yet recruiting
Countries Canada
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Crohn Disease
Additional Details

Crohn's disease is a chronic inflammatory condition affecting all segments of the digestive tract from the mouth to the anus. This condition is associated with an increased risk of relapses throughout the course of the disease. Nearly 25% of patients with Crohn's disease are in the pediatric age range. Many epidemiological data are in favor of an increase incidence of pediatric Crohn's disease. Environmental factors could explain this increased incidence. Among them sunlight exposure and vitamin D deficiency have been suggested by many authors. Recent studies have described how varying doses of oral vitamin D supplementation can alter serum levels of 25 hydroxyvitamin D (25(OH)D), but no study has specifically addressed the question as to whether vitamin D supplementation can alter the rate of relapse/complications and/or quality of life in children diagnosed with CD. Current treatments of CD at diagnosis are effective around the time of diagnosis, but in the short and long term, some of these therapies are inefficient or lead to allergic or intolerance reactions. Altogether the rate of relapses in the year after diagnosis is significant. Thus, different therapeutic approaches must be investigated with the aim of lowering the burden of the disease. From November 2012 to July 2013, we conducted an open label pilot cohort study aiming to investigate the bioavailability and tolerance of high doses of vitamin D3 (3,000 IU or 4,000 IU per day) administered orally as an adjunct therapy in 20 children with newly diagnosed pediatric CD (http://clinicaltrials.gov/ct2/show/NCT01692808). Data from laboratory studies, observational research and pilot trials taken together suggest that vitamin D can be of great importance in the genesis and progression of CD. Vitamin D deficiency could be a true risk factor for disease occurrence and/or relapses. The results of our pilot study demonstrate that in children with active CD at diagnosis, a daily dose of 4,000 IU of vitamin D is well tolerated and quickly increases the blood levels of 25OHD3 to 100 nmol/L or above in 100% of children with CD at diagnosis. Moreover a maintenance dosage of 2,000 IU a day is required (and sufficient) for maintaining this target over several months. Currently there is no adequately powered study in the pediatric CD population exploring the relationship between vitamin D therapy at diagnosis and CD outcomes. We propose a randomized controlled trial (RCT) to study the efficacy of high-dose oral vitamin D, as adjunct therapy, in children diagnosed CD, to reduce the relapse rate and to improve patients' quality of life. Primary Efficacy End Point: The proportion of patient with at least one relapse 52 weeks after randomization. Secondary efficacy endpoint: Quality of life scores, Cumulative steroid dose, Time to first relapse, Duration of corticotherapy, Number of relapses, Number of hospitalizations Safety Endpoint : incidence of hypercalcemia (defined as a corrected serum calcium level >2.65 mmol/L), incidence of hypercalciuria (defined as urinary calcium to creatinine molar ratio ≥1.50), incidence of supra-optimal levels of 25OHD3 as defined by a serum level ≥ 250 nmol/L, rate of study discontinuation due to hypercalcemia or hypercalciuria. Efficacy Variable: Occurrence of relapse, Time to relapse, Change in QoL score from baseline to 26 weeks, 52 weeks. Change in physical activity score from baseline to 26 weeks, 52 weeks

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

CHU Sainte-Justine, Montréal, Quebec, Canada

Status

Address

CHU Sainte-Justine

Montréal, Quebec, H3T 1C5

Montreal Children's Hospital, Montréal, Quebec, Canada

Status

Not yet recruiting

Address

Montreal Children's Hospital

Montréal, Quebec, H3H 1P3

Site Contact

Ernest Seidman, MD

ernest.seidman@mcgill.ca

514-934-1934 #44385

Hospital for Sick Children, Toronto, Ontario, Canada

Status

Not yet recruiting

Address

Hospital for Sick Children

Toronto, Ontario, M5G 1X8

Site Contact

Thomas Walters, MD

thomas.walters@sickkids.ca

416-813-7734

London Health Sciences Centre, London, Ontario, Canada

Status

Not yet recruiting

Address

London Health Sciences Centre

London, Ontario, N6A 5W9

Site Contact

Dhandapani Ashok, MD

dhandapani.ashok@lhsc.on.ca

519-685-8792

McMaster University, Hamilton, Ontario, Canada

Status

Not yet recruiting

Address

McMaster University

Hamilton, Ontario, L8N 3Z5

Site Contact

Robert Issenman, MD

issenman@mcmaster.ca

905-521-2100 #75637

Children's Hospital, Winnipeg, Manitoba, Canada

Status

Not yet recruiting

Address

Children's Hospital

Winnipeg, Manitoba, R3A 1S1

Site Contact

Wael El-Matary, MD

welmatary@exchange.hsc.mb.ca

204-787-1039

BC Children's Hospital, Vancouver, British Columbia, Canada

Status

Not yet recruiting

Address

BC Children's Hospital

Vancouver, British Columbia, V6H 3V4

Site Contact

Kevan Jacobson, MD

kjacobson@cw.bc.ca

604-875-2332

Stollery Children's Hospital, Edmonton, Alberta, Canada

Status

Not yet recruiting

Address

Stollery Children's Hospital

Edmonton, Alberta, T6G 1C9

Site Contact

Hien Huynh, MD

hien.huyhn@alberta.ca

780-248-5420

Alberta Children's Hospital, Calgary, Alberta, Canada

Status

Not yet recruiting

Address

Alberta Children's Hospital

Calgary, Alberta, T3B 6a8

Site Contact

Jennifer Debryun, MD

jennifer.debruyn@alberta.healthservices.ca

403-955-7211

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to our Terms, Conditions & Privacy.